Morgan Stanley Downgrades Akoya Biosciences to Equal-Weight, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has downgraded Akoya Biosciences (NASDAQ:AKYA) from Overweight to Equal-Weight and lowered the price target from $4 to $3.
August 06, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has downgraded Akoya Biosciences from Overweight to Equal-Weight and reduced the price target from $4 to $3.
The downgrade from Overweight to Equal-Weight and the reduction in the price target from $4 to $3 by Morgan Stanley is likely to negatively impact investor sentiment and the stock price of Akoya Biosciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100